Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pomalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 18/20 | 1.00 |
| ▸ | DDB1 known ✓ | Q16531 | 17/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 2/20 | 1.00 |
| ▸ | IL1B | P01584 | 2/20 | 1.00 |
| ▸ | IKZF1 | Q13422 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pomalidomide SCHEMBL29382107 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930059 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930061 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL369172 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL931134 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930065 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL19250920 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL20525239 | 0.99 | CRBN (0.97) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL20525246 | 0.99 | CRBN (0.97) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL20525238 | 0.99 | CRBN (0.97) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994302-A | Tubocapsenolide A-based PROTACs and preparation and application thereof | 沈阳药科大学 | 2024-11-22 | — | — | CN | claimed |
| CN-116496296-A | Dolutegravir derivative with anti-tumor function and preparation method thereof | 河南师范大学 | 2023-07-28 | — | — | CN | claimed |
| EP-1285916-B1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORP (US) | 2010-03-10 | — | — | EP | claimed |
| EP-1285916-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2003-02-26 | — | — | EP | claimed |
| US-12583837-B2 | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-116747316-B | PROTAC small molecule preparation method and application | 中南大学湘雅二医院 | 2026-01-16 | — | — | CN | disclosed |
| EP-4048279-B1 | 2-(2,6-DIOXOPIPERIDIN-3YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1. 3-DIONE FOR USE IN TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | CELGENE CORP (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-3952880-B1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE FOR USE IN THE TREATMENT OF NON-HODGKIN LYMPHOMA | CELGENE CORP (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | JUNO THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | MULLER GEORGE W (US) | 2002-12-05 | — | — | US | disclosed |
| US-6476052-B1 | Isoindolines, method of use, and pharmaceutical compositions | CELGENE CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | disclosed |
| US-6335349-B1 | AGENTS THAT REDUCE LEVELS OF TUMOR NECROSIS FACTOR; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; TREATMENT OF AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6316471-B1 | TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6281230-B1 | TREATING INFLAMMATION, INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE IN A MAMMAL | CELGENE CORPORATION | 2001-08-28 | — | — | US | disclosed |
| EP-0925294-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998003502-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | CRBN 1039/4885DDB1 1157/4885IKZF3 283/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | CRBN 1039/4885DDB1 1157/4885IKZF3 283/4885 |
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | ICOS, MDM2, XIAP | CRBN 17/4885DDB1 1046/4885IKZF3 54/4885 |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | TNF, TNFRSF1A, TRAF2 | CRBN 3437/4885DDB1 1125/4885IKZF3 790/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | CRBN 4469/4885DDB1 3697/4885IKZF3 1543/4885 |
| US-12583837-B2 | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the same | MEF2D, MAP2, MYADM | CRBN 4367/4885DDB1 1174/4885IKZF3 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.